The Prognostic Value of Telomerase Expression in Peripheral Blood Mononuclear Cells of Head and Neck Cancer Patients

Objectives Previously, we attempted to identify SCCA-derived HLA-A24 restricted peptides (SCCA112–120 and SCCA215–224) able to induce peptide-specific CTLs in lung, uterine cervix, and esophageal HLA-A24 + cancer patients. However, in head and neck HLA-A24+cancer patients, CTL induction using these peptides has not been investigated. We studied CTL induction by these peptides in head and neck HLA-A24+ cancer patients. Methods Peripheral blood mononuclear cells of SCC-cancer patients or healthy donors were stimulated in vitro with SCCA-derived peptides, which were prepared based on the HLA-A24 binding motif. The cytotoxity and peptide-response to target cells was investigated by both 51Cr release assay and IFN-gamma production. Results SCCA112–120-specific CTLs were generated in PBMCs from 6 head and neck cancer patients, but not in PBMCs from healthy donors. SCCA215–224 peptide generated CTLs in PBMCs from 5 head and neck cancer patients, but not in PBMCs from healthy donors. SCCA112–120 and SCCA215–224 peptide were able to induce cancer-reactive CTLs in the peripheral blood mononuclear cells of HLA-A24+ head and neck cancer patients. Conclusions These SCCA-peptides may thus be useful for specific immunotherapy for HLA-A24+ head and neck cancer patients.

Download Full-text

Prognostic value of microRNA-10b overexpression in peripheral blood mononuclear cells of nonsmall-cell lung cancer patients

Tumor Biology ◽

10.1007/s13277-015-3366-6 ◽

2015 ◽

Vol 36 (9) ◽

pp. 7069-7075 ◽

Cited By ~ 13

Author(s):

Yun-Long Yang ◽

Lu-Ping Xu ◽

Feng-Lin Zhuo ◽

Tian-You Wang

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Prognostic Value ◽

Mononuclear Cells ◽

Nonsmall Cell Lung Cancer ◽

Peripheral Blood Mononuclear ◽

Lung Cancer Patients ◽

Blood Mononuclear Cells

Download Full-text

α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [223Ra]RaCl2-treated prostate cancer patients

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-020-05170-6 ◽

2021 ◽

Author(s):

S. Schumann ◽

U. Eberlein ◽

C. Lapa ◽

J. Müller ◽

S. Serfling ◽

...

Keyword(s):

Prostate Cancer ◽

Dna Damage ◽

Cancer Patients ◽

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Absorbed Dose ◽

Peripheral Blood Mononuclear ◽

Absorbed Doses ◽

Blood Mononuclear Cells

Abstract Purpose One therapy option for prostate cancer patients with bone metastases is the use of [223Ra]RaCl2. The α-emitter 223Ra creates DNA damage tracks along α-particle trajectories (α-tracks) in exposed cells that can be revealed by immunofluorescent staining of γ-H2AX+53BP1 DNA double-strand break markers. We investigated the time- and absorbed dose-dependency of the number of α-tracks in peripheral blood mononuclear cells (PBMCs) of patients undergoing their first therapy with [223Ra]RaCl2. Methods Multiple blood samples from nine prostate cancer patients were collected before and after administration of [223Ra]RaCl2, up to 4 weeks after treatment. γ-H2AX- and 53BP1-positive α-tracks were microscopically quantified in isolated and immuno-stained PBMCs. Results The absorbed doses to the blood were less than 6 mGy up to 4 h after administration and maximally 16 mGy in total. Up to 4 h after administration, the α-track frequency was significantly increased relative to baseline and correlated with the absorbed dose to the blood in the dose range < 3 mGy. In most of the late samples (24 h – 4 weeks after administration), the α-track frequency remained elevated. Conclusion The γ-H2AX+53BP1 assay is a potent method for detection of α-particle-induced DNA damages during treatment with or after accidental incorporation of radionuclides even at low absorbed doses. It may serve as a biomarker discriminating α- from β-emitters based on damage geometry.

Download Full-text